| Name | Title | Contact Details |
|---|---|---|
Tram Dang |
Director, Information Technology & Support Services | Profile |
Dan Weston |
Director, Information Technology PMO | Profile |
Welcome to a different kind of CRO. Bringing your product to market takes something different. At Rho, we`re experienced, creative problem-solvers who provide outstanding clinical research fueled by our unique team approach. Our dedication to collaboration makes your clinical trials and programs run smarter and more efficiently.
Crescent City Surgical Centre is a Metairie, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Relay Therapeutics is building the world`s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. By placing protein motion at the heart of drug discovery, Relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. Headquartered in Cambridge, Mass., Relay Therapeutics is a private company launched in 2016. To date, Relay Therapeutics has raised $120M in financing from Third Rock Ventures, BVF Partners, GV (formerly Google Ventures), an affiliate of D.E. Shaw Research, Casdin Capital, EcoR1 Capital, Section 32 and Alexandria Venture Investments. Our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. If you`re creative, collaborative and passionate about making a difference in the lives of patients, join us!
Perlegen Sciences, Inc. is a Newark, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Cabaletta Bio is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. The Cabaletta Approach to selective B cell Ablation (CABA™) platform, in combination with Cabaletta`s proprietary technology, utilizes CAAR T cells that are designed to selectively bind and eliminate only specific autoantibody-producing B cells while sparing normal antibody-producing B cells, which are essential for human health. The Company`s lead product candidate, DSG3-CAART, is being evaluated in the DesCAARTes™ phase 1 clinical trial as a potential treatment for patients with mucosal pemphigus vulgaris, a prototypical B cell-mediated autoimmune disease. The FDA granted Fast Track Designation for DSG3-CAART in May 2020. For more information about the DesCAARTes™ Phase 1 clinical trial, please visit our website ( DesCAARTes™ Phase 1 Trial ). The Company`s lead preclinical product candidate, MuSK-CAART, is in IND-enabling studies and is designed as a potential treatment for patients with MuSK-associated myasthenia gravis.